VIVUS — Investor Presentation (November 2018)
20 slides from VIVUS's investor presentation, Nov 27, 2018
Slide 1: Forward Looking Statements; Non-GAAP Financial Measures
Forward Looking Statements Non-GAAP Financial Measures ©2018 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 2 Forward Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and are subje
Slide 2: Contents
Contents ©2018 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 3 •OverviewPage 4 •PharmaceuticalsPage 7 •AcquisitionsPage 14 •DebtPage 15 •FinancialsPage 17 •ReviewPage 19
Slide 3: Overview: Investment Highlights
Overview Investment Highlights ©2018 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 4 •Generated recurring positive non-GAAP EBITDA of $4.8M in Q3 2018. This is the first quarter VIVUS has generated positive EBITDA based on recurring revenue in the last ten years •Repurchased/restruct
Slide 4: Overview: Management Focus Next Months
Overview Management Focus Next 24 Months ©2018 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 5 •Drive Qsymia revenue and profitability with the Transformative Pharmaceutical Operating Model •Re-launch PANCREAZE in Q1 2019 •New sales team and excellent market insights •Leverage the Tr
Slide 5: Overview: Management Team
Overview Management Team • McKesson, BMS, OTN, BVCF, ORIX, Willow • Johnson & Johnson, Novartis, KRIM, Willow • Deloitte and Touche, Alexza Pharmaceuticals, Pharmacyclics, Incyte, • Wilson, Sonsini, Goodrich and Rosati P.C. • Glaxo Smith Kline, ICC, Novartis • Elan, Merck, Schering Plough, Sanofi Av
Slide 6: Pharmaceutical Assets
Pharmaceuticals Pharmaceutical Assets Track and Breakthrough Therapy designation ©2018 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 7 Pre-Clinical Phase 1 Phase 2 Phase 3 Approved PANCREAZE® -EPI due to Cystic Fibrosis + other conditions -Pancreatitis Qsymia® -Obesity (Discussions w
Slide 7: Qsymia is a safe and effective therapy for BMI management
Pharmaceuticals Qsymia is a safe and effective therapy for body mass index management Proprietary extended-release formulation combining low doses of active ingredients from two previously approved compounds, phentermine and topiramate 3-month data also support short-term use, with weight loss reduc
Slide 8: PANCREAZE indicated for exocrine pancreatic insufficiency
Pharmaceuticals • PANCREAZE is indicated for exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other conditions Pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreas glands Provides proven benefits to EPI patients Indicated for both pediat
Slide 9: VI-0106 PAH: Tacrolimus for Pulmonary Arterial Hypertension
Pharmaceuticals VI-0106 PAH • Tacrolimus for the Treatment of Pulmonary Arterial Hypertension (PAH) ©2018 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 10 PAH is a serious, rare, and progressive disease Progressive narrowing in pulmonary arteries, resulting in right heart failure and
Slide 10: PAH Clinical Overview
Pharmaceuticals PAH Clinical Overview The progressive narrowing in pulmonary arteries leading to heart failure ©2018 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 11
Slide 11: Worldwide Market for PAH Therapies
VIVUS Pharmaceuticals Worldwide Market for PAH Therapies $4500 $4 000 $3,500 $3 000 $2,500 $2000 $1,500 $1,000 $500 $-Adempas Adcirca Revatio Opsumit Letairis Tracleer •orentiram •Tyvaso •Remodulin •ventavis Flolan (.i_;:.' Cc/:J 0 ..c..:. ..... ] ::s ..... 0.6 0. NA! 2007 2008 2009 2010 2011 Year 2
Slide 12: Tacrolimus Experience in PAH Patients
Pharmaceuticals Tacrolimus Experience in PAH patients ©2018 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 13 •Compassionate use •3 end-stage patients, functional class 3 and 4 •Positive impact on clinical outcomes •Dramatically reduced rate of hospitalizations •Functional class impro
Slide 13: Asset Acquisition Philosophy
Acquisitions Asset Acquisition Philosophy ©2018 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 14 •As a core VIVUS activity, we are evaluating additional in-licensing and acquisition candidates that would meet our goals of meeting patients’ needs while working toward profitability and
Slide 14: Corporate Debt Alternatives
Debt Corporate Debt Alternatives ©2018 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 15 In order of current preference 1 Improve operating performance to generate enough recurring cash flow to pay down and refinance debt 2 Acquire asset(s) that generate $25M - $40M of annual non-GAAP
Slide 15: Debt Bridge November 2018 to May 2020
Debt Debt Bridge November 2018 to May 2020 $350 $300 $250 $200 $150 $100 $50 $0 $291.4M of Total Debt Nov 2018 $181.4M Pay Off Convertible Debt May 2020 $216.4M Total Debt May 31st 2020 • As of May 2020 based on current internal projections of EBITDA, VIVUS should be able to support senior secured d
Slide 16: Financial Snapshot
Financials Financial Snapshot (in $MM, except per share data) Company Name Ticker Current Share Price (11/26/2018) 52 Week High 52 Week Low Vivus, Inc VVUS $ $ $ 2.90 9.90 3.30 Plus: Debt (Principal value) Convertible Notes, due 2020 Senior Secured Notes, due 2024 Less Cash and Investments 190.0 110
Slide 17: Operating Results
Financials Operating Results 2017 Revenue: 2017 2018 Q4 Q1 Q2 Q3 LTM (in $MMs, except per share data) License and milestone revenue 7,500 - - - - - Royalty revenue 2,483 664 585 668 1,126 3,043 Operating expenses: Amortization of intangible asset 544 91 91 1,273 3,638 5,093 Selling and marketing 16,
Slide 18: Review: Management Focus Next Months
Review Management Focus Next 24 Months ©2018 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 19 •Drive Qsymia revenue and profitability with the Transformative Pharmaceutical Operating Model •Re-launch PANCREAZE in Q1 2019 •New sales team and excellent market insights •Leverage the Tra
Slide 19: Thank You
Thank You ©2018 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 20
Slide 20: VIVUS Thank You
20 VIVUS Thank You (©2018 VIVUS Inc. llrightsreserved. INNOVATIVE THERAPIES-NOVEL PRODUCTS. ww.vivus.com | Nasdaq: VVUS.